All In Biotech

Drug Trial Radar · NCT03828539

Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine

Head-to-head Study of Erenumab Against topiRamate-a Double-blind, Double Dummy Migraine Study to Assess Tolerability and Efficacy in a patiEnt -Centered Setting

Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 777 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

777

Actual

Start

Feb 22, 2019

Primary completion

Jul 29, 2020

Study completion Jul 29, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could have failed up to three prophylactic treatments out of: propranolol/metoprolol, amitriptyline, flunarizine. Patients were stratified into groups according to their number of migraine days during the baseline period.

Conditions

  • Migraine

Interventions

  • ErenumabBiological

    70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks

  • TopiramateDrug

    Film-coated tablet taken orally: 25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase.

  • Erenumab matching placeboBiological

    Erenumab matching placebo pre-filled syringue administered every 4 weeks

  • Topiramate matching placeboDrug

    Topiramate matching placebo administered daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE)Time frame: 24 Weeks

Locations

79 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Alzenau in Unterfranken, Germany

  • Novartis Investigative Site

    Bad Homburg, Germany

  • Novartis Investigative Site

    Bad Honnef, Germany

  • Novartis Investigative Site

    Bad Saarow, Germany

  • Novartis Investigative Site

    Bayreuth, Germany

  • Novartis Investigative Site

    Bergen, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bielefeld, Germany

  • Novartis Investigative Site

    Böblingen, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Celle, Germany

  • Novartis Investigative Site

    Chemnitz, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Dillingen, Germany

  • Novartis Investigative Site

    Erbach im Odenwald, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Gelsenkirchen, Germany

  • Novartis Investigative Site

    Greifswald, Germany

  • Novartis Investigative Site

    Haar, Germany

  • Novartis Investigative Site

    Halle, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Heidenheim, Germany

  • Novartis Investigative Site

    Hoppegarten, Germany

  • Novartis Investigative Site

    Ibbenbueren, Germany

  • Novartis Investigative Site

    Jena, Germany

  • Novartis Investigative Site

    Jülich, Germany

  • Novartis Investigative Site

    Kassel, Germany

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.